Prognostic scoring systems in SM
Parameter . | REMA (for ISM) . | MAPS . | IPSM . | MARS . | GPS . | |||
---|---|---|---|---|---|---|---|---|
OS . | PFS . | Nonadvanced . | Advanced . | OS . | PFS . | |||
WHO (advSM) | + | |||||||
Age ≥60 y | + | + | + | + | ||||
Anemia, g/dL | ||||||||
≤10 | + | |||||||
≤11 | + | + | ||||||
Thrombocytopenia, × 109/L | ||||||||
<100 | + | + | + | |||||
<150 | + | |||||||
Leukocytosis, × 109/L | ||||||||
≥16 | + | |||||||
Increased serum markers | ||||||||
Baseline serum tryptase | + | + | ||||||
β2-microglobulin | + | + | ||||||
Alkaline phosphatase | + | + | + | |||||
Genetics | ||||||||
BM KIT D816V VAF ≥1% | + | |||||||
Additional somatic mutations | + (A/R/D) | + (A/R/D) | + (A/R/NRAS) | + (S/A/R) | + (S/A/R/D) |
Parameter . | REMA (for ISM) . | MAPS . | IPSM . | MARS . | GPS . | |||
---|---|---|---|---|---|---|---|---|
OS . | PFS . | Nonadvanced . | Advanced . | OS . | PFS . | |||
WHO (advSM) | + | |||||||
Age ≥60 y | + | + | + | + | ||||
Anemia, g/dL | ||||||||
≤10 | + | |||||||
≤11 | + | + | ||||||
Thrombocytopenia, × 109/L | ||||||||
<100 | + | + | + | |||||
<150 | + | |||||||
Leukocytosis, × 109/L | ||||||||
≥16 | + | |||||||
Increased serum markers | ||||||||
Baseline serum tryptase | + | + | ||||||
β2-microglobulin | + | + | ||||||
Alkaline phosphatase | + | + | + | |||||
Genetics | ||||||||
BM KIT D816V VAF ≥1% | + | |||||||
Additional somatic mutations | + (A/R/D) | + (A/R/D) | + (A/R/NRAS) | + (S/A/R) | + (S/A/R/D) |
Adapted from Muñoz-González and Orfao85 with permission.
A, ASXL1; D, DNMT3A; GPS, global prognostic scoring system; R, RUNX1; S, SRSF2.